Literature DB >> 33112014

Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic.

Susana Armesto1, Carmen González Vela2, Julia Sánchez3, Aitziber Illaro3, Jesús Mayorga3, Ana E López Sundh1, Cristina Naharro Fernández1, Natalia Palmou4, Cristina Gómez-Fernández1, Marcos A González López1, Miguel A González-Gay4.   

Abstract

Entities:  

Year:  2020        PMID： 33112014     DOI： 10.1111/dth.14464

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN： 1396-0296            Impact factor:   2.851


× No keyword cloud information.
  2 in total

1.  Interleukin-17 Inhibitor Combination Therapies for the Treatment of Psoriasis: A Systematic Review.

Authors:  Amylee Martin; Akshitha Thatiparthi; Jeffrey Liu; Jashin J Wu
Journal:  J Clin Aesthet Dermatol       Date:  2022-06

2.  Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review.

Authors:  Mette Gyldenløve; Farzad Alinaghi; Claus Zachariae; Lone Skov; Alexander Egeberg
Journal:  Am J Clin Dermatol       Date:  2022-06-23       Impact factor: 6.233
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.